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A COMPARISON OF TWO QUALITY OF LIFE INSTRUMENTS
IN PATIENTS WITH UPPER GASTROINTESTINAL CANCER
SA Goodbrand 1, J Thomson 2, L Bartelemes 1, PA Levack 2,
AM Thompson 1
1 Department of Surgery and Molecular Oncology, University of 
Dundee, Dundee, United Kingdom, 2 Macmillan Cancer Team, 
Dundee, United Kingdom
Quality of life (QoL) is of particular importance in upper gastrointestinal
cancer where only a third of patients have operable disease and palliation 
may be difﬁ   cult. The aim of this study was to compare two QoL
instruments EORTC QLQ-C30 and  SEIQoL-dw, a patient centred 
questionnaire, in patients with oesophageal, gastric or pancreatic cancer.
Consecutive patients with oesophageal  (n=33), gastric  (n=18) or 
pancreatic (n=11) cancer completed both the EORTC and SEIQoL-dw
questionnaires at diagnosis and for 20 patients with oesophageal or 
gastric cancer 6-weeks into treatment for palliation of disease.  
The male: female ratio was 5.3: 1 and mean age 73 years (range 55-85). 
There was signiﬁ  cant correlation  between the two QoL tools  (Pearson 
correlation 0.82, P<0.01), although this reﬂ  ected a correlation in emotional 
functioning  (Pearson correlation 0.3, P<0.05)  but not in physical 
functioning. EORTC tool gave lower mean QoL scores than SEIQoL-dw 
(table 1) but for both tools, the QoL declined over the 6 week period.
Table 1: Oesophageal cancer Gastric cancer
Before After Before After 
(n=33) (n=12) (n=18) (n=8)
EORT 53.3 21.3 55.1 28.4
SEIQoL-dw 69.7 52.6 73.4 50.0
Although there were correlations between the two QoL tools, different
domains were important using the two questionnaires, with family
and home issues rated above health in SEIQoL-dw where the patient 
chooses the 5 most important domains.
Given the multi-dimensional nature of QoL, future studies of QoL
in patients with upper gastrointestinal cancer should include patient-
centred tools such as SEIQoL.
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SAFETY AND EFFICACY OF USE OF BONANNO SUPRAPUBIC 
CATHETER TO DRAIN MALIGNANT PLEURAL EFFUSION
M Moe, A Hussain, Singleton Hospital, Swansea, United Kingdom
Objectives: Despite the availability of licensed small-bore chest tubes
(eg. Seldinger portex system) Bonanno suprapubic urinary catheter has
been used in UK hospitals. The Bonanno catheter has smaller diameter
(2.1 mm) than proper chest tubes (2.33 to 4.67 mm) ever studied. This
study evaluates the safety and efﬁ  cacy of use of Bonanno catheter to
drain malignant pleural effusions, and use of different systems in other
UK hospitals.
Study design: Retrospective study on pleurocenteses done with Bonanno
catheter  in one oncology  department, and UK postal questionnaire
survey regarding use of different systems and Bonanno catheter in other
hospitals (Survey was conducted in August 2001.). 
Findings: 134 pleurocenteses in 80 cancer patients were evaluated. Total
drainage = 279.15 litres for 127 procedures (data not available for 7
procedures); range = 0 – 10 litres; mean = 2.25 litres. Complications
included  local pain  (10.4%); pneumothorax  (4.5%);  blockage and
falling out (1.5% each); broken tube requiring surgical removal (0.7%).
After pleurodesis with Bleomycin ( 17 patients) and Tetracycline (19
patients) twelve patients in each group did not require any further
drainage in next 30 days. 70 out of 118 hospitals replied questionnaires
(62% response rate). Use of different systems were Bonanno catheter:
14 (20%) hospitals; conventional standard tube = 58 (83%) hospitals;
Pigtail catheter under ultrasound guidance = 34 (48%)  hospitals  (it
was the sole method used in 3 hospitals); Seldinger portex system =
12 (17%) hospitals. 42 (60%) of hospitals didn’t have any knowledge
of use of Bonanno catheter for chest drainage. Six hospitals reported
experiencing tube blockage, kink, splitting, fracture, slow drainage and
pneumothorax with Bonanno catheter. 
Conclusions: Bonanno catheter is effective and relatively safe. Tube
fracture and kink are the main problems. Similar system with blunt-
tip trocar needle, ﬂ  exible and kink-resistant catheter will be an ideal to
drain malignant pleural effusion.
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WEEKLY CISPLATIN AND ORAL ETOPOSIDE FOR PLATINUM
RESISTANT OVARIAN CANCER
S Clive 1, DJ Storey 1, C Cullen 2, N Dixon 2, Rye T 2, M MacKean 1,
JF Smyth 2, H Gabra 3
1 Edinburgh Cancer Centre, Edinburgh, United Kingdom, 2 Cancer 
Research UK, Edinburgh, United Kingdom, 3 Imperial College,
London, United Kingdom
Studies have suggested high response rates in platinum resistant ovarian
cancer using a regime of weekly cisplatin and daily oral etoposide. We report
our experience of this regime in a non-selected group of platinum resistant
patients.
Patients (pts) with progressive epithelial ovarian cancer who were resistant to
platinum were offered weekly cisplatin 60mg/m2 for 6/8 weeks and daily oral
etoposide 50mg for 4/8 wks (induction) followed by oral etoposide 50mg for 
up to 9 mths (maintenance). Toxicity, quality of life (QOL) and response data
were prospectively collected.
21 pts (med age 59(44-68), PS 1(0-2), med 2(1-3) previous chemotherapy
regimes) were treated.  14 (67%) were platinum refractory (PD <4mths post
platinum), 6 (28%) platinum resistant (PD <6mths post platinum and 1 had 
PD 8 mths post platinum, with med platinum free interval 5(0-11) mths. The
1st 5 pts had cisplatin in N saline and 3/5 did not complete induction because
of toxicity. 16 received cisplatin in hypertonic saline, enabling higher dose
intensity. 7/16 did not complete induction after a med 3 wks cisplatin (3
PD, 3 toxicity). Induction caused delays of med 2(0-4) wks for toxicity (2
patients had no delays).  Incidence of grade 3/4 toxicities during induction
was: neutrophils 47%, platelets 18%, anaemia 9%, neurotox 3%, vomiting
3%. 3 pts had neutropenic sepsis of whom 1 died. 11 pts started maintenance.
1/11 had 9 cycles of etoposide, 4 continue after med 4 cycles, 6 had med 
3(2-7) cycles.  There was 1 CR (maintained >28 wks), 3 PR, 4 SD (2/4 with
>75% CA125 response), 12 NE (4/12 with >75% CA125 response) and 1 PD
giving a total scan response of 19% but total scan and/or CA125 response
of 48% for a median of 16 (6-28 wks).  Full analysis of QOL is awaited but
global QOL did not appear to change signiﬁ  cantly between cycles 1 and 2.
Wkly cisplatin/oral etoposide is active in platinum resistant ovarian cancer.
However in heavily pre-treated, progressing pts, it is associated with
signiﬁ  cant neutropenia and should be used with caution.
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GENETIC ANTICIPATION IN FAMILIAL PANCREATIC CANCER
CD McFaul 1, R Kress 2, DK Bartsch 2, H Rieder 2, M Sina-Frey 2,
JP Neoptolemos 1, W Greenhalf 1
1 The University of Liverpool, Liverpool, United Kingdom,
2 Phillips-University, Marburg, Germany
An estimated 10% of  pancreatic cancers are inherited. Familial
Pancreatic Cancer (FPC) is an autosomal dominant disease. Genetic
anticipation refers to the earlier age of onset of familial diseases in
successive generations. EUROPAC (the European Registry of Hereditary
Pancreatitis and Familial Pancreatic Cancer) and FaPACa (German
National Case Collection) have combined their databases in order to
investigate the reports of anticipation in FPC. This has given us clues
to the nature of the disease gene and is vital for linkage analysis. The
database has 115 families with pancreatic cancer, 104 from EUROPAC
and 11 from FaPaCa. Individuals were assigned to one of three “Hsu”
generations (G1, G2 and G3) depending on their position within the
family tree (as described by Hsu et al (2000) Genet Epidemiol, 18, 17-
32). Comparison of the age between pairings of affected parents and
children indicates that children die from pancreatic cancer 10 years
earlier than their parents. This is statistically signiﬁ  cant but potentially
represents bias. To allow for unaffected individuals we carried out
Kaplan-Meier analysis comparing the three  “Hsu” generations (logrank
p<0.01). This remained statistically signiﬁ   cant even when limiting
observation time to an equal (60 year) period, allowing consideration of
individuals born up to the year 1943 (p<0.01). 
If t here  is no generation effect on the age of pancreatic cancer we
would predict that the age related r isk  from one generation could
be used to accurately predict the number of pancreatic cancer cases
seen in any other generation (regardless of the period of observation).
This was found not to be the case and prediction of cancer required
a progressively  increasing cancer risk per generation  (anticipation).
Therefore, anticipation does NOT appear to be a statistical anomaly
and we present arguments that anticipation  is genetic rather than
environmental.
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THE CAREGIVER DISTRESS SCALE, A USEFUL TOOL TO
ASSESS THE NEEDS OF CARERS
EM Rankin, E Wilkie, R Earl
United Kingdom, Division of Cancer Medicine, University of Dundee,
Dundee
There is evidence of signiﬁ  cant distress in the carers of patients with
cancer (reviewed Eur.J Cancer 2003 39 1517).  Our work and that of 
others has shown that the carers’ requirements are frequently unmet, and 
that sometimes patients block access of carers to sources of support and 
information (Eur J Cancer Care 2002 11 183).  A simple tool to direct
intervention to help the carer in the routine clinical setting is required. 
Cousins et al (Br J Clin Psychol 2002 41 387) developed a brief 17
point scale to assess distress – the Caregiver Distress Scale (CDS)
using carers of patients with Parkinsons’ disease.  In a preliminary
study to test the utility of the tool, we have used this scale so far in 37
consecutive carers who also completed the Beck Depression inventory
and Spielberger State Trait Anxiety Inventory.  Patients separately ﬁ  lled 
in the CDS as if they were answering for their carer. 
Carers found the tool easy to use.  The CDS was completed by 92%
of pairs indicating high acceptability.  The results showed considerable
underestimate by the patient of the distress experienced by the carer 
in areas concerning personal cost (Spearman’s rank correlation 0.381,
p0.046) care-receiver demands (Spearman’s r 0.64, p0.013), social r
impact (Spearman’s r 0.485, p0.009) and emotional burden (Spearman’s r
r 0.670, p<0.001).   There was a signiﬁ   cant correlation between r
depression in the carer and the perceived emotional burden (p=0.002)
and personal cost (p=0.024) of the carer.  Trait anxiety correlated with
perceived social cost of their role to the carer (p=0.019).
The CDS is a useful, easily administered tool which takes 5 minutes
to complete.  Analysis of the carer’s score is rapid, enabling the health
professional to target attention to areas of distress.  This should lead to
better outcomes and improve the carer’s level of satisfaction with their 
role.
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MULTI-MODALITY TREATMENT IN PRIMARY BONE
LYMPHOMA – A SINGLE INSTITUTION’S EXPERIENCE
D Ford 1, D Wilson 1, S Sothi 2, R Grimer 3, D Spooner 1
1 United Kingdom, University Hospital Birmingham, Queen Elizabeth
Medical Centre, Birmingham, 2 United Kingdom, Walsgrave NHS
Trust, Coventry, 3 United Kingdom, Royal Orthopaedic Hospital,
Birmingham
Background g : Primary bone lymphoma (PBL) is a rare disease, with limited
speciﬁ  c published data concerning optimal management. We describe the
experience of a tertiary referral centre in treating PBL with multi-modality
therapy (chemotherapy, radiotherapy and surgery).
Methods: Patients with a diagnosis of PBL were identiﬁ  ed using the hospital
data base. Data pertaining to diagnosis, stage, treatment and outcome were
collected retrospectively. 
Patient Characteristics: Between 1985 and 2003, 22 patients (10 M; 12 F),
median age 50 years (range 18-89), with histologically conﬁ  rmed PBL were
treated; 19 had high grade histology, 2 low grade, 1 not graded.17 had stage
IE disease and 5 stage IV . International prognostic indices (IPI) were 13 low
risk, 8 intermediate and 1 high risk.
Treatment: All patients received chemotherapy (1 chlorambucil/ vincristine
for low grade disease, 2 MCOP, 13 CHOP, 5 CHOP-Methotrexate, 1
CAPOMET). Additional local treatment was given to 21 patients; 18
received radiotherapy (30-50Gy in 10-25 fraction), median BED10of 48Gy,
(α/β ratio 10 Gy, range 39-60 Gy). 3 patients had surgery alone as local
treatment (2 endoprosthetic replacement (EPR) and 1 ﬁ  bulectomy). 
Results: Median follow-up is 84.5 months (range 2-206). 4 patients have
died, 3 with  disease at the time of  death. 18 patients remain alive and
disease free; 1 patient has required second line chemotherapy and remains
disease-free at 45 months, and 1 patient has developed a second malignancy
(Hodgkin’s disease). Actuarial 10 year survival is  85% for low risk IPI and
66% for intermediate IPI. 10 year relapse free survival is 88% for low risk
and 71% for intermediate risk IPI. Complications included 1 patient with
avascular necrosis and 1 patient with a pathological fracture after biopsy.
Conclusion:  Systemic chemotherapy,  followed  by  local t herapy with
radiotherapy or surgery, produces excellent results for PBL.
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PRIMARY B-CELL LYMPHOMA OF THE SKIN
L El-Helw, BW Hancock, D Stater 
YCR Academic Unit of Clinical Oncology, Weston Park Hospital, 
Shefﬁ  eld, United Kingdom
The clinical presentation, treatment and outcome were retrospectively
evaluated in a series of 66 patients with primary B-cell lymphoma of the
skin, referred to our centre between 1984 and 2003.
  The lymphoma database was searched and clinical records were reviewed.
Absence of any detectable extracutaneous lesion and the expression of B cell
restricted antigens by neoplastic cells were the essential criteria for selection
of cases.
The cohort included 37 (56%) males and 29 (44%) females with a mean
age of 59 years. The most commonly involved site was the trunk and the
disorder typically showed non aggressive clinical behaviour; the majority
of the patients presented with stage I (82%) and/or low grade (50%) disease
with a tendency to remain localised to a limited area of the skin. Follicular 
lymphoma was the most common histologic subtype (35%), the next most
frequent was the diffuse large cell lymphoma (32%). The majority (47%)
of patients were treated w ith radiotherapy  for  localised  disease whereas
chemotherapy was given in 20% of patients, with single agent chlorambucil
being most frequently used. Surgical excision as the sole modality of 
treatment was adequate in 33%.
Disease free survival (DFS) was 91% at 1 year, 82% at 2 years and 60% at 5
years. DFS was signiﬁ  cantly lower with older age (> 45 years), leg lesions,
generalised and multiple lesions, and for those treated with chemotherapy.
The survival at 5 and 10 years was 80%. The  histologic grade,  leg
involvement and the number of lesions were the most signiﬁ  cant variables
affecting overall survival. Only 7 patients died of lymphoma.
In conclusion primary cutaneous B cell lymphoma represents a peculiar and 
relatively homogenous entity concerning clinical behaviour, response to
treatment, and overall prognosis. It is a condition with an excellent survival
rate compared to other extranodal non-Hodgkin’s lymphomas. Treatment
should  be tailored to each  individual patient according to number and 
distribution of the lesions, histology, and general condition of the patient.
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AN EVALUATION OF A TEACHING SESSION FOR JUNIOR 
DOCTORS CONDUCTING DO NOT ATTEMPT RESUSCITATION 
DISCUSSIONS WITH TERMINAL CANCER PATIENTS
DW Fyfe 1, B El Khoury 2, V Crosby 3, G Walker 2
1 Nottingham City Hospital, Nottingham, United Kingdom, 2 Queens 
Medical Centre, Nottingham, United Kingdom, 3 Hayward House 
Hospice, Nottingham, United Kingdom
Objective
To evaluate whether communication skills training in discussing “Do Not
Attempt Resuscitation”  (DNAR)  decisions with patients with terminal
cancer is perceived to be needed by and of beneﬁ  t to junior doctors.
Design
A single short training session covering communication skills in approaching
and conducting DNAR discussions, with evaluation by questionnaires before
and approximately 2 months after.
Setting
Junior doctors’ teaching programme at two Teaching Hospitals.
Participants
Senior and Junior (Pre-registration) House Ofﬁ  cers from both medical and
surgical specialities.
Results
55 junior doctors participated in 5 teaching sessions: 29 senior and 26
junior house ofﬁ   cers.  78% had conducted a DNAR discussion in the
previous 3 months (median 3 discussions each). 43% had received some
form of  previous DNAR teaching.  All felt they could improve on at least
some aspects of discussing DNAR. 85% scored the session as relevant or
very relevant. The follow-up questionnaire response rate was 62%: 79% of
responding doctors felt that the training session had changed their practice;
conﬁ  dence levels had increased in 65%; their median conﬁ  dence score in
discussing DNAR had improved from 3 to 4  (on a scale of 0-5).
Conclusion
A single teaching session on how to discuss DNAR with terminal cancer
patients was found to have a positive subjective impact on practice.  Teaching
communication skills in how to conduct DNAR discussions should form an
integral part of junior doctor training.
Posters
S41
British Journal of Cancer (2004) 91(Suppl1), S24–S80 & 2004 Cancer Research UKP69
DETECTION OF HUMAN PAPILLOMAVIRUS DNA TYPES 16 AND
18 IN CERVICAL ADENOCARCINOMA AND ITS PRECURSORS 
BY PCR
Magdy El-Mansi, ARW Williams, RG Morris, 
Edinburgh Medical School, Edinburgh
Objective: To determine the prevalence of human papillomavirus
(HPV) types16 and 18 in cervical adenocarcinoma and its precursors
of Scottish patients. Methods: HPV DNA was extracted from parafﬁ  n-
embedded, formalin-ﬁ  xed tissues of 161 specimens of 139 patients,
including 119 cases of invasive adenocarcinoma and 20 of pre-invasive
precursors (high grade CGIN). HPV DNA was detected by PCR test
using type speciﬁ  c primers from the E6 gene and   6 E7 gene of HPV type 7
16 and HPV type 18 followed by restriction enzyme digestion. Results:
Out of  a total of 139 women with various cervical adenocarcinomas
lesions, HPV DNA was identiﬁ  ed in 87 cases (62.6%) in which, HPV16
was negative for 74 (53%) and positive for 65 (47%) patients and 
HPV18 was negative for 98 (71%) and positive for 41 (29%) patients.
Genotyping by RFLP and PCR revealed that HPV type 16 was the most
frequent type of HPV detected, comprising 46 cases (33%), followed by
HPV type 18 in 22 cases (16%), and HPV type16 and HPV type 18 in
19 cases (14%). There were 52 (38%) of 139 of patients with various
cervical adenocarcinoma lesions with HPV type16 and HPV type 18
both negative. HPV typing in all cases of 16 normal cervical biopsies
was negative with both HPV type 16 and HPV type 18. Conclusions:
Our ﬁ  ndings support that HPV16 (mainly), along with HPV18, may play
a role in pathogenesis of cervical adenocarcinoma and its precursors.
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EPIRUBICIN-CARBOPLATIN-CAPECITABINE (ECARBOX) IN
RELAPSED OVARIAN CANCER: A PHASE I/II TRIAL
R Hubner, T Ahmad, A Rigg, S Kaye, I Gibbens, C Keyzor,
A Prouse, M Gore
Royal Marsden Hospital NHS Trust, London, United Kingdom
Background: We have previously shown the combination of epirubicin,
cisplatin, and prolonged  infusional 5-ﬂ  uorouracil  (5-FU)  is active  in
relapsed epithelial ovarian cancer (EOC). Capecitabine (Xeloda, X) is an
orally bioavailable tumour selective ﬂ  uoropyrimidine, it has proven efﬁ  cacy
and is more convenient than infusional 5-FU. We have performed a phase I/II
study of ECarboX in relapsed EOC.
Method: Patients (pts) with relapsed EOC with an interval of at least 6
months from platinum-based ﬁ  rst line treatment, received bolus iv epirubicin
50mg/m2 and iv carboplatin AUC 5 on day 1, and capecitabine either 750mg/
m2 (level 1) or 1000mg/m2 (level 2) daily in two divided doses throughout
a 21-day cycle, or 1000mg/m2 daily for days 1-14 of a 21-day cycle (level
3). Pts were planned to receive 6 cycles. The primary endpoint was the
maximum tolerated dose (MTD).
Results: At dose level 1 two pts completed 6 cycles and one pt 4 cycles of
treatment. Seven cycles were delayed, and 50% dose reductions in epirubicin
and capecitabine were required in two pts: one pt had recurrent grade 3
neutropenia, the other had grade 3 neutropenia, lethargy and diarrhoea, and
was subsequently withdrawn for prolonged (>2 week) grade 2 neutropenia
despite dose reduction. At level 2, four out of ﬁ  ve pts completed 6 cycles, the
ﬁ  fth received 2 cycles. There were 11 treatment delays: 2 pts had 25% dose
reductions and 1 pt was withdrawn from the study due to prolonged grade 3
neutropenia. Four pts experienced grade 2 haematological toxicity and one
pt had grade 3 lethargy. At level 3, three pts have received at least 3 cycles
each, and a further 3 pts at least 1 cycle. There have been 4 treatment delays
and two 25% dose reductions, both for grade 2 neutropenia. Eleven pts are
evaluable for response: 8 pts have obtained a partial or complete response, 1
pt has stable disease, and only 2 pts have progressed.
Conclusions: The MTD was level 2, capecitabine 1000mg/m2 for 21 days of
a 21-day cycle. Capecitabine on days 1-14 of a 21-day cycle is likely to be
better tolerated and is being further explored.
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MEAT, COOKING METHODS AND RISK OF COLORECTAL
CANCER: A CASE-CONTROL STUDY
L. Yaghjyan
American University of Armenia, Yerevan, Armenia
Objectives: The study aimed to explore an association between meat
consumption, its cooking methods and risk of colorectal cancer.
Study Methods/Design: The study utilized a case-control design.
Seventy-seven patients diagnosed with colorectal cancer during the
period from August 17, 2002 to August 20, 2003 were included in the
study as cases.  The control group was selected from healthy hospital
visitors, who were free of the disease, and were not related to the
patient.  The controls were matched with the cases by age and gender.
Information was collected using telephone or face-to-face interviews by
means of interviewer-administered questionnaires.
Results: The analysis showed that the risk of having colorectal cancer 
increased with everyday meat use compared with not-daily meat use
(adjusted for frequency of fried and boiled sausage use and preference
of fried meat surface: OR=3.2; 95% CI 1.0- 18.5; p-value 0.044), with
preference of heavily browned surface of fried meat compared with
lightly browned (adjusted for daily meat use and frequency of fried and 
boiled sausage use: OR= 15.4; 95% CI 2.8-85.8; p-value 0.002).  There
was no statistically signiﬁ  cant risk of having colorectal cancer across
different types of meat as well as across preferred cooking methods
for different meat types.  The results of the study have also shown a
protective effect of frequent use (more than once/week) of boiled and 
fried sausage use on risk of colorectal cancer (adjusted for daily meat
use and preference of fried meat surface: OR=0.03; 95% CI 0.004-
0.3; p-value 0.002, and OR=0.1; 95% CI  0.008-0.5; p-value 0.008,
respectively).  
Conclusions: Risk of colorectal cancer increased with everyday meat
use and preference of heavily browned meat surface, and decreased with
frequent use of boiled/fried sausages.
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DETERMINATION OF GALECTIN 3 LEVELS IN THYROID
TUMOURS BY REAL-TIME PCR AND LOCALISATION BY
IMMUNOCYTOCHEMISTRY.
NG Powell 1, LA Stephens 1, S Jeremiah 1, RM Tuttle 2,
TI Bogdanova 3, MD Tronko 3, DW Williams 1, GA Thomas 1
1 Human Cancer Studies Group, Swansea University, Swansea,
United Kingdom, 2 MSKCC, New York, United States, 3 Institute of 
Endocrinology and Metabolism, Kiev, Ukraine
Galectin-3  (Gal-3)  is a beta-galactoside-binding protein  implicated  in  a
number of functions, including cell proliferation and differentiation, cell
adhesion, angiogenesis, apoptosis, and cell survival. Alterations in the levels
of Gal-3 mRNA and protein and in its intracellular localisation suggest that
it plays important role in tumourigenesis in a variety of tissues.  There have
been few direct comparisons of mRNA levels with protein localisation.  We
compared  gal-3 mRNA levels by quantitative PCR (QPCR) and protein
localisation by immunocytochemistry (ICC) in paired samples of tumour and
normal tissue from 50 cases of papillary carcinoma (PTC) and 14 cases of
cellular follicular adenoma (FA) from Ukraine.  PTCs showed elevated levels
of  Gal-3 mRNA on QPCR relative to normal tissue (Wilcoxon test p< 1.209
x 10-6), and predominantly universally positive staining in the cytoplasm of
the follicular cells comprising the tumour. Nuclear positivity was observed
in nearly all PTCs, but this was not marked.  Gal-3 ICC showed positive
staining only in endothelial cells in the normal thyroid tissue, whether
derived  from patients with PTC or FA.  Endothelial staining was not seen
within PTCs.   FAs, in contrast to  PTCs showed a lower level of gal-3 RNA
on QPCR compared to paired normal t issue  (Wilcoxon test p< 3.209 x
10-5).  On ICC, only two of the adenomas showed localisation of gal-3 to
the follicular cells; the majority showed negative follicular epithelium, but
marked positivity of endothelial cytoplasm within the tumour.  In two FAs,
areas of tumour with nuclear and cytoplasmic changes similar to that seen in
PTCs showed strong cytoplasmic positivity for gal-3 protein.
These results suggest  that gal-3 may be a useful marker for distinguishing
PTC from follicular tumours, but not a suitable for tool in preoperative
diagnosis for determining malignancy in follicular tumours.  The differences
in endothelial positivity between PTCs and FAs are intriguing and warrant
further investigation.
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CARBOPLATIN + DOXORUBICIN (CD) AND CARBOPLATIN
+ PACLITAXEL (CP) GIVEN AS A SEQUENTIAL DOUBLET IN 
ENDOMETRIAL CANCER (EC) AND MIXED MESODERMAL
TUMOURS (MMT).
RNH Shah, M Everard, C Keyzor, K Hall, R Ahern,
ME Gore, SB Kaye
The Royal Marsden Hospital, Sutton, United Kingdom
Platinum, anthracycline and taxane based regimens are active in advanced/
recurrent EC and MMT. However, the toxicity of concurrent 3-drug regimens
may preclude their routine use in a palliative setting. We are performing a
feasibility study using a sequential doublet consisting of 4 cycles of CD
(C=AUC5, D=50mg/m2,  d1q21)  followed  by 4 cycles of CP (C=AUC5,
P=175mg/m2, d1q21) in patients (pts) with advanced/recurrent Stage III/IV
EC, MMT and gynaecological malignancy where the histological differential
lies between endometrial and ovarian cancer. We hypothesise that this would 
allow all 3 drugs to be given with acceptable tolerability. 19 pts have
enrolled, of whom 15 have completed all planned therapy. Diagnosis is EC in
14 pts and MMT in 5 pts. Median age is 56.
Pts have received 126 cycles of chemotherapy of a planned maximum of 134
(94%). Of these 126 cycles, 23 were delayed by 1 week and 3 by 2 weeks.
Reasons for delay were exclusively haematological (73% neutropenia, 27%
thrombocytopenia). Dose reductions occurred 5 times and were continued 
for subsequent cycles in any given patient. Causes for dose modiﬁ  cation were
myalgia (1pt), parasthesia (1pt) and neutropenia (3pts). Non-haematological
toxicity was as expected and included universal alopecia. Grade II toxicity
consisted of nausea (2pts), vomiting (2pts), constipation (1pt), myalgia (1pt)
and sepsis (1pt). Grade III toxicity consisted of myalgia (1pt) and parasthesia
(1pt). No grade IV non-haematological toxicity was seen.
Response data in 11 pts with measurable/evaluable disease shows CR in 3
pts, PR in 6 pts and PD in 2 pts. Disease was non measurable throughout in 5
pts. 2 pts have died to date, one of PD after 4 cycles and another after 7 cycles
having initially responded.
Our data suggest this sequential doublet is a feasible regimen, combining
tolerable toxicity with  impressive response data, and warrants further 
investigation.
P72:2
MOTIVATING SMOKING CESSATION TO REDUCE THE RISK OF
CERVICAL CANCER
S Hall 1, TM Marteau 1, AJ Bishop 1, H Kitchener 2, P Hajek 3
1 United Kingdom, Institute of Psychiatry, Kings College London, 
London, 2 United Kingdom, University of Manchester, St. Mary’s 
Hospital, Manchester, 3 United Kingdom, Queen Mary’s School Of 
Medicine and Dentistry, Barts and The London Hospitals, London
P72:3
SPACE-TIME CLUSTERING ANALYSES OF CHILDHOOD 
CANCERS SUPPORTS A COMMON INFECTIOUS AETIOLOGY
RJQ McNally 1, OB Eden 2, FE Alexander 3, AM Kelsey 2, JM Birch 1
1 United Kingdom, Cancer Research UK Paediatric and Familial
Cancer Research Group, Manchester, 2 United Kingdom, Central
Manchester and Manchester Children’s University Hospitals NHS 
Trust, Manchester, 3 United Kingdom, University of Edinburgh,
Edinburgh
In previous studies we demonstrated s igniﬁ  cant  space-time clustering
amongst cases of ALL, astrocytoma, soft tissue sarcoma and Wilms’ tumour.
We hypothesised that there may be a common aetiology particularly between
some of these diagnostic groups. The aim of the present study was to test
this hypothesis by analysing for cross-clustering between cases in different
diagnostic groups. Cases included in a population-based childhood cancer 
registry during the period 1954-2001 were analysed. Knox tests for space-
time interactions between cases were applied with ﬁ  xed thresholds of close
in space, <5km and close in time, <1 year apart, to determine whether there
are more pairs occurring in close proximity than expected by chance. Tests
were repeated replacing geographical  distance with  distance to the  Nth
nearest neighbour [NN] to adjust for population density. N was chosen such
that the mean distance was 5km. Data were also examined by a second order 
procedure based on K-functions to allow for multiple testing and boundary
effects. Reference points in time and space were dates and addresses at birth
and diagnosis respectively.
All four methods showed statistically signiﬁ  cant (p<0.05) cross-clustering
between cases of HD and astrocytoma, ALL and astrocytoma, and ALL
and NHL, based on time and place of birth; between cases of NHL and 
PNET’s, and AML and peripheral neuroectodermal tumours, based on time
and place of diagnosis; between cases of ALL and PNET’s, and ALL and 
peripheral neuroectodermal tumours, based on time of diagnosis and place
of birth; between cases of ALL and peripheral neuroectodermal tumours
based on time of birth and place of diagnosis. There was little evidence of 
cross-clustering between Wilms’ tumours, soft tissue sarcomas and other 
malignancies respectively.
These ﬁ  ndings are consistent with a common infectious aetiology for certain
haematological and neural malignancies in children.
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PHARMACOKINETIC MEASUREMENTS OF A 5FU PRO-DRUG, 
CAPECITABINE, IN BLADDER TUMOURS  OVER-EXPRESSING 
THYMIDINE PHOSPHORYLASE
Y-L Chung 1, H Troy 1, IR Judson 2, R Leek 3, MO Leach 2, M Stubbs 1, 
AL Harris 3, JR Grifﬁ  ths 1
1 United Kingdom, St George’s Hospital Medical School, London, 2
United Kingdom, Institute of Cancer Research, Surrey,
3 United Kingdom, John Radcliffe Hospital, Oxford
Capecitabine is a prodrug of 5-ﬂ  uorouracil  (5’FU). The ﬁ   nal step of
conversion is from 5′deoxy-5-ﬂ  uorouridine (5′DFUR) to 5’FU by thymidine
phosphorylase (TP) in tumours. Previous studies have shown that tumour
response is strongly correlated with TP levels in tumours.  The aims of this
study were: a) to investigate the pharmacological roles of TP by measuring
the pharmacokinetics (PK) of capecitabine; b) to develop the use of PK
measurements of capecitabine  by  19F MRS as a non-invasive surrogate
marker for determining TP levels in tumours. 
Human bladder xenografts were grown subcutaneously in MF1 nude mice.
TP over-expressing (2T10) and control (wild-type (RT112) and empty-
vector (EV11)) tumours were examined. When tumours were established
(~500mg), mice were given a single dose of capecitabine (360mg/kg in
DMSO i.p) or 5’DFUR (200mg/kg in DMSO i.p). 19F spectra were acquired
and t he rate constant of capecitabine  breakdown, the  build-up of t he
intermediate molecules (5’DFCR/5’DFUR) and the subsequent breakdown
of t he molecules were determined.  The rate constant of t he 5’DFUR
breakdown was also evaluated. 
The rate constant of t he  breakdown of t he  intermediate molecules was
signiﬁ  cantly faster in the 2T10 tumours than in the control group.  No
signiﬁ  cant  differences  in the rate of capecitabine  breakdown or the
accumulation of t he  intermediate molecules were observed. The rate
constant of the breakdown of 5’DFUR in the 2T10 tumours was found to be
doubled when compared with the controls. 
This study conﬁ  rmed the expected pathway of capecitabine metabolism
and it also showed that the level of TP is related to the rate of 5′DFUR
conversion. Using in vivo 19F MRS to measure the pharmacokinetics of
capecitabine and  its  intermediate metabolites  in tumours may provide  a
non-invasive surrogate method for determining TP levels in tumours and for
predicting tumour response to capecitabine in patients.
ABSTRACT WITHDRAWN
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DUODENO-OESOPHAGEAL REFLUX ENHANCES MUTAGEN 
INDUCED OESOPHAGEAL CARCINOGENESIS
Z Bell 1, C Menezes 1, P Bonde 1, C Swarbrick 3, J Sloan 3,
S Mirvish 4, J McGuigan 2, FC Campbell 1
1 United Kingdom, Surgery, Cancer Centre, The Queen’s University of 
Belfast, Belfast, 2 United Kingdom, Cardio-thoracic surgery, Cancer 
centre, The Queen’s University of Belfast, Belfast, 3 United Kingdom,
Pathology, School of Medicine, The Queen’s University of Belfast, 
Belfast, 4 United Kingdom, Eppley Institute for Research in Cancer, 
University of Nebraska Medical Centre, Omaha
Introduction: Epidemiological evidence points to an association between 
gastro-oesophageal reﬂ  ux  disease and t he rising  incidence of oesophageal
cancer in the western world. Reﬂ  ux of duodenal content may be particularly
implicated in carcinogenesis but its precise role and magnitude of effects are
unclear.
Aim: The aim of this study was to assess the effect of duodenal reﬂ  ux on 
oesophageal tumourigenesis, either alone or in combination with a human 
dietary carcinogen, methyl-n-amyl-nitrosamine (MNAN).
Methods: Reﬂ  ux was promoted by duodeno-oesophageal anastomosis without 
gastric bypass, in male Sprague Dawley rats. Effects of reﬂ  ux alone or in 
combination with MNAN (IP injection, 25mg/kg/wk x 4 weeks) were assessed 
upon inﬂ  ammatory changes, metaplasia, dysplasia and carcinoma. Rats were
randomly assigned to 4 groups: control (n=9), MNAN alone (n=39), reﬂ  ux alone
(n=39) and reﬂ  ux + MNAN (n=50). Animals were sacriﬁ  ced at 38 weeks. 
Results: Groups varied s igniﬁ  cantly  (ANOVA) w ith regard to
inﬂ  ammation(INF), metaplasia (MP), dysplasia (DYS) and carcinoma (CA).
Control
%
MNAN
%
Reﬂ  ux
%
Reﬂ  ux + 
MNAN %
p-value
INF 0 2.6 48.7 60 <0.001
MP 0 0 30.8 24 <0.01
DYS 0 15.4     38.5 54 <0.001
CA 0 2.6 2.6 16 <0.05
Conclusions: Duodeno-oesophageal reﬂ   ux promotes oesophageal
carcinogenesis in a step-wise progression from inﬂ  ammation to metaplasia,
dysplasia and invasive carcinoma. In addition, dietary carcinogen exposure may
enhance this risk.
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THE INFLUENCE OF POSITRON EMISSION TOMOGRAPHY 
(PET) IN CHANGING TREATMENT OPTIONS IN LOCALLY
ADVANCED AND METASTATIC COLORECTAL CANCER (CRC).
C Thomas, Z Kassam, W Wong, M Harrison
Mount Vernon Cancer Centre, London, United Kingdom
Introduction
Increasing treatment options (including the potential for cure) have led to
a more complex treatment algorithm in advanced colorectal cancer. More
detailed  diagnostic and  functional  imaging  is required to offer patients
optimal therapy. PET scanning offers additional conﬁ  rmation or refutation
of the presence of metastatic disease whilst also deﬁ  ning the extent of the
disease.
Aim
To assess the changes in management following PET scanning in patients
with advanced CRC.
Method
All patients with advanced CRC are routinely staged with spiral CT +/-
MRI. Additional PET scanning was performed  if t he original  imaging
was inconclusive about disease extent. Forty three (43) PET scans were
performed, for this reason, over a 24 month period starting 1/1/02. 
Patient characteristics: average age 61.9 years (23-79); male: female ratio
1.5:1; Primary site: rectum (27), sigmoid (7), colon (2), caecum (7); Dukes
stage: B (10), C (29), unknown (4).
Results
Additional information, above that already available, was provided in
30 patients  (70%). Previous staging assessment was conﬁ  rmed  in the
remainder. In the 30 patients 20 were upstaged, 9 downstaged and 1 showed
a differential response to previous therapy. Management was changed in 22
(51%) of these patients. An economic analysis is currently being undertaken
and will be presented.
Conclusion
Within this cohort of patients 22 (51%) had their management signiﬁ  cantly
changed as a result of PET scanning. This appears to be a practical and
cost-effective form of diagnostic imaging for patients with advanced CRC.
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INFRARED MICROSPECTROSCOPY IN CANCER DIAGNOSIS
MJ Tobin 1, Ma Chesters 1, J Chalmers 1, Se Fisher 2, Fjm Rutten 3,
Im Symonds 3, A Hitchcock 3, Ka Maclennan 2, R Allibone 3,
S Dias-gunasekara 1
1 United Kingdom, Cclrc, Daresbury, 2 United Kingdom, University 
Of Leeds, Leeds, 3 United Kingdom, University Of Nottingham, 
Nottingham
Infrared m icrospectroscopy  is capable of  detecting subtle  biochemical
changes within tissues. The brightness of the synchrotron source combined 
with microscope access brings the potential to examine tissue at single cell
level. We have used this approach to study oral epithelial tumour tissue
using synchrotron infrared microspectroscopy.
Material for analysis was prepared from excised tumour specimens using
fresh frozen, air dried tumour sections at 5µm thickness. Spectra were
collected from areas identiﬁ  ed visually as tumour and stroma respectively.
After correction  for water vapour contributions, all s pectra were
normalised to the peak height of the amide II absorption, which has been
used successfully elsewhere. The region of the remaining spectrum was
subjected to multivariate analysis using the Pirouette software package
(Infometrix, Inc, Woodville, USA). 
Mid infrared absorption spectra, collected at cellular spatial resolution
gave results which were sufﬁ  ciently distinct to distinguish between three
different cell types (malignant, stromal and keratinised) when analysed 
using principal component analysis.
The resulting data were robust enough to achieve correct classiﬁ  cation of 
cells from subsequent specimens.
These results conﬁ  rm the promise of this new and advancing technology
as a future tool for cancer diagnosis in that they show the ability of IR 
microspectroscopy, together with multivariate data analysis to predict
subtle chemical  differences  between cell t ypes within a tumour. The
potential for use in tissue diagnosis merits further exploration, especially
in view of the technical improvements that are being made in laboratory
level detectors and the ability of this technology to aid pathological tumour 
diagnosis.
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DETERMINATION OF [18F]FLUOROTHYMIDINE KINETICS IN 
TUMOUR AND NORMAL  TISSUES OF  PATIENTS WITH BREAST
CANCER USING POSITRON EMISSION TOMOGRAPHY .
L Kenny 1, A Al-Nahhas 1, S Shousha 1, S Osman 2,
DM Vigushin 1, RC Coombes 1, EO Aboagye 1
1 Imperial College London, London, United Kingdom, 2 Hammersmith
Imanet, London, United Kingdom
Aim: T he aim of t his study was to model t he tissue  kinetics of
[18F]ﬂ  uorothymidine ([18F]FLT ) positron emission tomography (PET) data
in order to derive indices of cellular proliferative capacity. 
Background:  [18F]FLT  is a substrate  for mammalian thymidine  kinase
1 (TK1) gene product.  TK1 expression increase in the G1-phase of the
cell c ycle making  [18F]FLT a potential radiotracer  for  imaging cellular
proliferation in vivo. Quantitative analysis by mathematical modelling can,
thus, provide parameters that reﬂ  ect proliferative potential.
Methods: E ight tumour areas from  ﬁ  ve  patients with  locally a dvanced
or metastatic epithelial  breast cancer (lobular carcinoma and  ductal
carcinomas) were analysed in this study. [18F]FLT was administered by
intravenous injection followed by dynamic imaging for 90 minutes. Arterial
blood samples were analysed by γ-counting and high performance liquid γ-counting and high performance liquid  γ
chromatography to derive an arterial input function. Data-led spectral
and  graphical  (Patlak) analyses were performed and compared to semi-
quantitative uptake data (SUV).
Results: [18F]FLT kinetics in tumour showed a linear ﬁ  t with mean ± s.e.
KI values (net irreversible clearance of radiotracer from plasma to tissue)
of 4.71±0.71 x 10-4 (ml plasma/ml of tissue/sec) indicating retention. A
kinetic component approximating the decay constant for ﬂ  uorine-18 was
seen in spectral analysis modelling that was consistent with the KI parameter.
Radiotracer delivery (K1) and fractional retention at 90 min compared to 1
min (FRT) were 0.003±0.0005 ml plasma/ml of tissue/sec and 0.14±0.03,
respectively. The SUV at 90 min was 7.925±1.0825 m2/ml. KI, SUV , FRT
and K1 were higher in a ductal carcinoma with high Ki-67 labelling than in a
lobular carcinoma with low labelling index.
Conclusion: The  kinetics of  [18F]FLT can be modelled  by spectral and
graphical methods to yield parameters that may be related to proliferative
capacity.
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3’-DEOXY-3’-[18F]FLUOROTHYMIDINE AND 2-[18F]FLUORO-
2-DEOXY-D-GLUCOSE AS MARKERS OF RESPONSE TO 
CISPLATIN THERAPY IN VIVO
J Leyton, M Perumal, H Dhaliwal, J Litago, E Aboagye 
Hammersmith Hospital Campus, London, United Kingdom
Cisplatin is one of the most widely used chemotherapeutic agent in
the treatment of cancer, with wide ranging effects on solid tumours.
The aim of this study was to establish whether [18F]ﬂ  uorothymidine
([18F]FLT) and [18F]ﬂ  uorodeoxyglucose ([18F]FDG) could be used as
markers to determine early response to cisplatin therapy.
RIF-1 tumour bearing mice were untreated or treated with cisplatin
at single i.p. dose of 5 mg/kg. [18F]FLT and [ 18F]FDG were injected 
intravenously before or at 24 and 48 h after drug treatment. The tissue:
blood radioactivity ratios(T:B) were determined from biodistribution
studies at 60-min post radiotracer injection. The molecular determinants
of [18F]FLT uptake, thymidine kinase 1 (TK1) protein and ATP levels,
were assessed by western blot and bioluminescence, respectively.
Proliferating cell nuclear antigen (PCNA) status was determined.
T:B for [18F]FLT  pre-treatment, 24 h and 48 h post-treatment were
1.35±0.14, 1.13±0.2 and 1.18±0.11, respectively. This was not
statistically signiﬁ   cant. Corresponding values for [18F]FDG were
10.84±4.2, 8.34±1.9 and 6.12±1.4, which was signiﬁ  cant (p=0.03) at 48
h. Tumour volume decrease by 55% at 48 h post treatment. The decrease
in  [18F]FDG uptake correlated with PCNA labelling index (r=0.55;
p=0.01). Compared to pre-treatment levels, TK1 protein decreased at 24
h (24.4±11.07%, p=0.01), with partial recovery at 48 h (38.3±22.1%).
In contrast, a time dependent decrease in ATP levels was observed at 24
and 48 h post-treatment (p=0.05).
From this initial biodistribution study, [18F]FDG was a more speciﬁ  c
marker of response to cisplatin therapy. Changes in [18F]FLT uptake
could be explained in part by the changes in TK1 levels. Positron
emission tomography studies are ongoing to fully characterise the
radiotracer kinetics.
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CORRELATIVE STUDY OF SPIRAL CT FEATURES AND 
ANGIOGENESIS IN HAPATOCELLULAR CARCINOMA
B Wang 1, ZQ Gao 2, DX Yu 1, YH Shi 1
1 Department of Radiology, the Afﬁ  liated Hospital, Weifang Medical 
University, Weifang, China, 2 Department of Medical Biology, Weifang
Medical University, Weifang, China
Introduction Hepatocellular carcinoma (HCC) is a high vascular supply
tumour. The angiogenesis is one of the most important phenomena in the
process of HCC happening, and the process of the angiogenesis is also
the necessary in the growth and metastasis of the tumour. Our study is
to study the correlation between the contrast enhancement features
on spiral CT (SCT) and microvessel density (MVD), diameter and
expression location of F-VIII RA in HCC, and the relation between
SCT features and clinicopathological data.
Materials and Methods Fifty cases (54 lesions) of HCC proved
pathologically and examined with enhancement dual-phase SCT scanning
(the arterial and the portal vein phase) were included. The expressions
F-VIII RA were detected with immunohistochemical SP method. The
features of HCC in SCT were compared with the immunohistochemical
results of F-VIII RA and clinical and histopathological characteristics of
HCC.
Results Immunohistochemical results showed t hat the percentage of
capillary-like type, sinusoid-like type and mixed type was 24.1% (13/54),
18.5% (10/54) and 57.4% (31/54) respectively. The mean of MVD and
microvessel diameter was 50.20 ± 13.89, 15.06 ± 7.76 µm respectively
in 54 lesions. There was signiﬁ  cantly correlation between MVD and the
size, ascites, Edmondson’s grade, and between microvessel diameter and
AFP value. The factors related with the enhancement style were MVD,
the degree of necrosis and invasion, and the key factor related with the
pseudocapsula style were Edmondson’s grade and microvessel diameter. 
Conclusion Some  biological  behavior of HCC may  depend o n
angiogenesis, and the features of spiral CT may reﬂ  ect angiogenesis in
HCC to some degrees.
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TUMOUR DOSE RESPONSE TO 5,6-DIMETHYLXANTHENONE-
4-ACETIC ACID (DMXAA) ASSESSED BY IN VIVO MAGNETIC 
RESONANCE SPECTROSCOPY
LD McPhail 1, YL Chung 1, B Madhu 1, S Clark 2, JR Grifﬁ  ths 1,
LR Kelland 2, SP Robinson 1
1 United Kingdom, St. George’s Hospital Medical School, London,
2 United Kingdom, Antisoma Research Laboratories, London
DMXAA is a low molecular weight drug that induces the occlusion and 
collapse of established tumour blood vessels.  The aim of this study was
to investigate the dose response of murine HT29 xenografts to DMXAA
using magnetic resonance spectroscopy (MRS) and identify early, relevant
biomarkers associated with tumour response.  In vivo 31P and 1H MRS was
used to assess the bioenergetic status of HT29 tumours prior to and 6 hours
after treatment with either 0, 7.5, 15, 21 or 25 mg/kg DMXAA.  Following
in vivo MRS tumours were excised and both high resolution MRS and HPLC
were performed on tumour extracts.  A section of the tumour was also used 
for histological analysis of necrosis.
The  in vivo 31P-MRS  data showed a dose-dependent  decrease  in  high-
energy phosphates and increase in low energy phosphate treatment.  This
was associated with a dose-dependent increase in lactate observed using in
vivo 1H-MRS.  The 1H-MRS extract data showed a signiﬁ  cant increase in
free choline and a signiﬁ  cant decrease in glycerophosphocholine (GPC).
The in vivo dose response was further supported by the HPLC studies on
tumour extracts.  Importantly, there was no apparent correlation of metabolic
changes with the degree of necrosis observed by histology. 
The decrease in tumour energetics observed using 31P-MRS indicates that
DMXAA is starving the tumour of its energy supply.  The increase in free
choline (a precursor of membrane phospholipid) and decrease in GPC (an
end product of membrane degradation) suggests that DMXAA is causing
a reduction in tumour cell proliferation and membrane turn-over.  The
increase in lactate after drug treatment is consistent with vascular shut-
down as pyruvate, the end-product of glycolysis, is reduced to lactate
under anaerobic conditions. The lack of correlation between the in vivo
MRS data and histology suggests that in vivo MRS affords an early, non-
invasive assessment of tumour response to DMXAA, and therefore may have
potential for use in clinical trials.
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SR4554 AS A NON-INVASIVE PROBE OF TUMOUR HYPOXIA
DETECTED BY MAGNETIC RESONANCE SPECTROSCOPY: 
RESULTS OF A PHASE I TRIAL
CP Lee 1, GS Payne 2, RR Ruddle 1, FI Raynaud 1, SK Tan 1,
MJ Campbell 3, M Tracy 4, JP McNamara 4, MO Leach 2,
IR Judson 1, P Workman 1
1 United States, Cancer Research UK Centre For Cancer Therapeutics,
The Institute of Cancer Research and The Royal Marsden NHS Trust, 
Sutton, 2 United Kingdom, Cancer Research UK Clinical Magnetic
Resonance Research Group, The Institute of Cancer Research and 
The Royal Marsden NHS Trust, Sutton, 3 United Kingdom, Drug
Development Ofﬁ  ce, Cancer Research UK, London, 4 United 
Kingdom, SRI International, Menlo Park, California
Introduction: SR4554 is a ﬂ  uorinated 2-nitroimidazole which is reduced and bound 
in hypoxic cells. It was designed for use as a non-invasive tumour hypoxia probe
detectable by 19F Magnetic Resonance Spectroscopy (MRS). The earlier part of our 
Phase I study of SR4554 showed a plasma T1/2of ~3.3 hr, and a maximum tolerated 
dose of 1400mg/m2 m2 m . The 2nd part of this study aimed to further investigate evidence of  d
SR4554 retention in tumour at 16 hr (5x T1/2) using MRS compared with measured 
plasma values. Methods: Eligibility criteria included tumours ≥ 3cm at a depth of 
≤ 4cm. 19F MRS measurements were performed using a 1.5T Siemens Vision MR 
system and a 5, 10 or 16cm dual resonant  1H/19F surface coil to approximately 
localise the signal to the tumour. All patients (pts) received SR4554 at 1400mg/m2 m2  m
(IV) followed immediately by an MRS scan (MRS #1). The 2nd MRS scan (MRS #2) d
was acquired at ~16 hr post-infusion to detect 19F signals indicative of tumour hypoxia 
following washout of parent SR4554 from tumour. The retention index (RI) (%) was
deﬁ  ned as (MRS #2/ MRS #1)*100. Pharmacokinetic (PK) studies were performed.
Results: 16 pts were enrolled. Toxicities: Grade 1 nausea and vomiting (n=2), Grade
1 rash (n=1). PK studies showed: mean Cmax = 97.6 ± 48.8 mg/L; mean T ± max = 0.86 ±
0.25 hr; mean T1/2 =3.8 ± 0.9 hr, mean V ± ss= 36.5 ± 17.0 L; clearance = 10.5  ± ± 4.7 L/hr. ±
Unlocalised MRS studies were acquired in 14/16 pts. SR4554 signals were seen in 
MRS #1 in all 14 pts. In MRS #2, SR4554 signals were above detection threshold in 8
pts, yielding a mean RI of 10.2 ± 6.6% (range 0.6-21.1%) compared with 2.96  ± ± 1.85 ±
% (range 0.63-7.33%) in plasma. MRS #2 data were below detection threshold in 6
pts. Conclusions: SR4554 at 1400mg/m2 m2  m was well-tolerated. We have demonstrated 
that SR4554 is retained in tumours relative to plasma and that the study is clinically 
feasible. The range of values for RI relative to plasma supports the hypothesis that this
may be a genuine indication of tumour hypoxia.
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IN VIVO SUSCEPTIBILITY CONTRAST MRI OF MURINE 
MODELS OF LIVER METASTASIS
TL Kalber 1, SP Robinson 1, FA Howe 1, AJ Ryan 2, JC Waterton 2,
JR Grifﬁ  ths 1
1 United Kingdom, St. George’s Hospital Medical School, London,
2 United Kingdom, AstraZeneca, Macclesﬁ  eld
Ultrasmall superparamagnetic iron oxide (USPIO) particles are iron oxide
crystals typically coated with a dextran-based coating with an overall particle
size of <50nm. They are selectively taken up by t he reticuloendothelial
system (macrophages and Kupffer cells) in the liver.  When placed in a
magnetic  ﬁ   eld, USPIO particles produce large magnetic susceptibility
inhomogeneities, resulting in a dramatic and positive enhancement of R2 and 
R2* relaxation rates and suppression of normal liver MRI signal intensity.
This can facilitate the subsequent detection of metastatic lesions, which
do not take up USPIO’s and  hence  “shine through” conspicuously on a
darkened background of normal liver parenchyma. To establish the duration
and magnitude of suppression of normal murine liver signal afforded by
a single  injection of USPIO particles, normal murine  liver R2* and R 2
were quantiﬁ  ed longitudinally for up to 50 days following administration
of 2.5mgFe/kg AMI-7228 (Ferumoxytol, Guerbet Europe).  AMI-7228
dramatically increased liver R2* and R2 at day 0. However, by day 10, liver 
R2* and R2 of mice administered AMI-7228 had recovered to normal (non-
USPIO loaded) levels.  
For the  investigation of metastatic  lesions, mice were intrasplenically
injected with  2x106 LS174T or SW1222 colorectal cells. Longitudinal R2*
and R2-weighted MRI prior to and following adminstration of 2.5mgFe/kg
AMI-7228 was then used to follow the development of metastatic deposits
within the liver. Metastases were detected as early as 20 days post i.s.
injection and their progression, which was clearly evident, monitored 
at subsequent timepoints up to 38 days. The data demonstrate proof-of-
principle of susceptibility-contrast MRI to investigate mouse models of liver 
metastasis and how this approach will be used to i) increase the understanding
of the basic pathophysiology of liver metastasis in vivo and ii) demonstrate the
utility of the MRI method for the detection of metastatic disease that can
potentially be translated onto conventional clinical MRI instruments.
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USE OF INTRINSIC-SUSCEPTIBILITY MAGNETIC RESONANCE
IMAGING TO ASSESS ACUTE TUMOR RESPONSE TO THE
VASCULAR-TARGETING AGENT ZD6126
SP Robinson 1, TL Kalber 1, FA Howe 1, DJO McIntyre 1,
JR Grifﬁ  ths 1, DC Blakey 2, L Whittaker 2, AJ Ryan 2, JC Waterton 2
1 United Kingdom, St. George’s Hospital Medical School, London,
2 United Kingdom, AstraZeneca, Macclesﬁ  eld
ZD6126 is a vascular-targeting agent that causes the selective destruction of
tumor blood vessels, cessation of blood ﬂ  ow and death of tumor cells due to
nutrient starvation, resulting in massive necrosis. We have previously shown
the antivascular effect of 50mg/kg ZD6126 on rat GH3 prolactinomas to be
profound 24 hours after administration. 
Intrinsic-susceptibility magnetic resonance imaging  (MRI),  in which
endogenous deoxyhaemoglobin can provide a source of image contrast, was
used to assess the response of rat GH3 prolactinomas to ZD6126.  Multi
gradient echo (MGRE) MRI was used to quantify the effective transverse
relaxation rate R2* which, in the absence of other changes, depends on tissue
deoxyhaemoglobin levels and hence may provide an acute index of changes
in tissue oxygenation.  We hypothesised that following treatment with
ZD6126, haemoglobin within erythrocytes would deoxygenate, resulting in
an increase in tumour R2*. 
Tumour R2* was measured prior to and either immediately (at 7, 14, 21, 28
and 35 minutes) following or 24 hours following administration of 50mg/kg
ZD6126.  A signiﬁ  cant increase in tumour R2* was measured as early as
14 minutes, reaching 116 ± 4% of baseline by 35 minutes after challenge,
consistent with an ischaemic insult induced by vascular shutdown/
collapse.  A strong positive correlation between baseline tumour R2* and
the subsequent increase in R2* measured 35 minutes after treatment was
obtained, suggesting that the baseline R2* can predict for the likelihood and
magnitude of subsequent tumour response to ZD6126.  In contrast, a highly
signiﬁ  cant decrease in tumour R2* to 45 ± 4% of baseline was found 24
hours after administration of ZD6126.  Both R2* responses were associated
with a decrease in tumour perfusion as measured by Hoechst 33342 uptake.
Interpretation of the R2* response is complex, yet changes in tumour R2*
may provide a convenient and early MRI biomarker for immediate detection
of tumour activity of vascular targeting agents.
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LINEAR DISCRIMINANT ANALYSIS CLASSIFICATION OF
BRAIN TUMOUR 1H MR SPECTRA: A COMPARISON OF
COMPLETE SPECTRA VERSUS QUANTIFICATION
KS Opstad, C Ladroue, JR Grifﬁ  ths, FA Howe 
United Kingdom, St. George’s Hospital Medical School, London
Pattern recognition analysis of  1H MRS brain tumour spectra may
provide a clinically valuable  diagnostic tool,  but  distinction of 
glioblastomas from metastases is currently difﬁ  cult. In this study we
investigate the use of pattern recognition of single voxel STEAM TE
30ms spectra to compare classiﬁ   cation using: i) the whole spectra
versus LCModel quantiﬁ  cation of 14 biochemicals; and ii) principal
component analysis  (PCA) versus manually chosen  biochemical
concentrations from LCModel quantiﬁ  cation.  Classiﬁ  cation  was
evaluated using leave-one-out linear discriminant analysis (LDA)
Histopathologically veriﬁ  ed tumours consisted of 7 astrocytoma grade
II (AS2), 15 meningiomas (MNG), 14 glioblastomas (GBM) and 10
metastases  (MET). Data reduction of whole spectra was performed 
using PCA. Manual selection of the quantiﬁ  ed biochemicals prior to
LDA was according to Mann Whitney U-test statistical comparisons
between tumour groups, for which we found the Cr, Ins, GSH and 
1.3ppm  lipid/macromolecule peaks showed t he greatest differences
between groups. Leave-one-out LDA classiﬁ  cation was performed on
the three types of reduced dataset for the following groups: I) AS2,
MNG and HG (high-grades comprising GBM + MET), II) AS2, MNG,
GBM and MET; and III) AS2, GBM and MET. 
LDA of GroupIon either whole spectra or 4 manually selected LCModel
concentrations gave similar result of 91% correct classiﬁ  cation. LDA of 
Group II resulted in much poorer classiﬁ  cation with between 59 - 80%
correct. LDA of Group III using PCA of the whole spectra or LCModel
quantiﬁ  cation was also poor with between 54 - 72% correct. In contrast,
using the Cr, Ins, GSH and 1.3ppm lipid  LCModel concentrations gave
87% correctly classiﬁ  ed spectra, and 83% between GBM and MET
alone. This suggests that PCA is not always optimal for data reduction
of spectra, and using prior knowledge of quantitative metabolite data
may give the best classiﬁ  cation.
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A 2.05PPM 1H MRS MOBILE LIPID CHARACTERISTIC OF
NON-NECROTIC METASTASIS
KS Opstad, JR Grifﬁ  ths, FA Howe
United Kingdom, St George’s Hospital Medical School, London
For patients with brain tumours, determination of tumour grade, and
differentiation of metastasis (MET) and glioblastoma  (GBM), are
clinically  important questions. Increased  lipids are associated w ith
increased malignancy, and the 2.02 ppm NAA peak with normal brain
tissue. We now report on a 2.05ppm resonance from mobile lipids
characteristic of some metastases.
Short echo (TE 30ms) 1H spectra were acquired at 1.5T from
histologically proven METs (n=22) and GBMs (n=20). In 6 MET
patients we observed a narrow peak at 2.05ppm: for 2 of these we
further acquired spectra with TE = 30, 60, 90 and 136ms and for 2
we acquired metabolite nulled spectra (TE 30ms with a pre-inversion
pulse).
The 2.05ppm peak was still present at the longest TE, and we determined
it to have an apparent T2 of ~140ms. In the metabolite-nulled spectra
the 2.05 peak was clearly present, whereas signals from metabolites
choline, creatine and lactate were nulled. Difference spectra revealed
only metabolites, indicating the 2.05 ppm peak has much shorter T1 than
metabolites, and so likely to be mobile lipid.
Our data indicate there is a mobile lipid moiety which gives rise to a
narrow peak at 2ppm, and has a longer apparent T2 relaxation time
than for other lipid/macromolecule peaks (T2 < 70ms) found in brain
tumours. This could be mistaken for an NAA signal in long TE spectra,
and so cause an underestimation of malignancy. We have identiﬁ  ed 6
metastasis spectra with this narrow 2.05ppm peak (assigned to the H in
the -CH2-CH2-CH= lipid group). All show similar spectral patterns, with
signiﬁ  cant choline, high lactate and low 1.3 (-CH2) and 0.9ppm (-CH3)
lipid peaks. The narrow 2.05ppm peak is not found in metastases spectra
with very high lipids. This suggests the narrow 2.05ppm peak relates to
hypoxic and/or cystic, but viable, tumour tissue prior to necrosis, and
possibly more likely associated with metastases.
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P53 INDEPENDENT RADIATION INDUCED BYSTANDER 
EFFECTS  INDUCED BY RADIOPHARMACEUTICALS
LABELLED WITH α−, β− AND AUGER EMITTERS
M Boyd, J Dorrens, S Ross, KW Tan, N Baig, MR Zalutsky,
RJ Mairs 
1 United Kingdom, CRUK Beatson Labs, Glasgow, 2 United Kingdom, 
Duke University, Durham, 3 United States, Glasgow School for Cancer 
Studies, Glasgow
Targeted radiotherapy is the selective irradiation of tumour cells by
radionuclides conjugated to tumour seeking molecules. Gene therapy can
expand the tumour types accessible to this type of therapy. We recently
introduced the noradrenaline transporter gene  (NAT) into tumour cells
endowing them with the capacity for uptake of radiolabelled MIBG. Current
cancer gene therapy strategies are however limited by low  gene transfer 
efﬁ  ciencies so cancer gene therapy strategies must have a component of 
collateral cell  kill to neighbouring cells. Utilising the radiation-induced 
biological  bystander effect  (RIBBE) to its  full potential could  increase
therapeutic efﬁ  cacy. WE adapted media transfer methodology to quantify the
contribution of RIBBE to cell kill in NAT transfected cells after exposure to
the β−emitter [131I]MIBG, the α-emitter [211At]MABG or the Auger emitter 
[123I]MIBG. The role of p53 in mediating RIBBE was investigated.
NAT transfected human cancer cells and their P53 null variants were
irradiated using a 60Co source or by incubation with radiopharmaceutical. An
amended media transfer protocol was employed to assess the magnitude of 
RIBBE contributing to cell kill from different targeted radiation qualities.
Dose-dependent RIBBE were identiﬁ  ed  in  human cancer cell  lines
following γ-ray external beam radiation. RIBBE were P53 independent. γ-ray  external  beam  radiation.  RIBBE  were  P53  independent.  γ
Treatment with [131I]MIBG,  [123I]MIBG and [211At]MABG showed a
substantial impact of RIBBE on cell clonogenic survival. Cell kill due to
RIBBE in cells never exposed to radiation was equal to that afforded by
radiopharmaceutical treatment . The level of RIBBE correlated with dose of 
radiopharmaceutical.
The  large RIBBE observed w ith radiopharmaceutical treatment of NAT
transfected cancer cells and t he  lack o f requirement  for  functional P53,
implies the feasibility of utilising this strategy to enhance the efﬁ  cacy of 
combined gene therapy and targeted radiotherapy.
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[131I]META-IODOBENZYLGUANIDINE AND TOPOTECAN
EXPERIMENTAL COMBINATION TREATMENT OF TUMOURS 
EXPRESSING THE NORADRENALINE TRANSPORTER
AG McCluskey, E Cosimo, M Gaze, M Boyd, RJ Mairs 
1 United States, CRUK Beatson Labs, Glasgow, 2 United Kingdom,
Middlesex Hospital, london
Introduction:  The aim of this study was to determine the efﬁ  cacy of
[131I]MIBG in combination with topotecan in vitro and in vivo.
Results:  Two cell lines, expressing the noradrenaline transporter
(NAT) were used in this study: SK-N-BE(2c) (neuroblastoma) and PN3
(NAT gene transfected  glioma cell line).  Three treatment schedules
were assessed: topotecan administered 24h  before  (i), after  (ii) o r
simultaneously with (iii) [131I]MIBG.  DNA breakage was evaluated
by comet assay and cytotoxicity by clonogenic survival.  Efﬁ  cacy was
measured by growth delay of tumor xenografts.
Supra-additivite clonogenic sterilisation was  achieved  by combination
schedules (ii) and (iii) but not (i).  The combination index values at the
IC50 level were (i) 1.379 (± 0.025) (ii) 0.761 (± 0.014) and  (iii) 0.880
(± 0.016).  This order of effectiveness of the sequence of treatments was
reﬂ  ected in their generation of long-term DNA damage:  in cells assayed
24h after treatment (to allow for DNA repair), signiﬁ  cant damage was
observed following schedules (ii) and (iii) (both p < 0.005), but not (i)
(NS).
The mean times required for a 10-fold increase in experimental tumor
volume, were 18.6 days (untreated), 31.9 days ([131I]MIBG alone), 25.3
days (TPT alone), 37.1 days (combination schedule (i)) and 49.7 days
(combination schedule (ii)) whereas combination schedule (iii) cured
100% of tumors.  This treatment caused no myelotoxicity, according to
platelet production or stem cell clonogenic capacity.
Conclusions: Long-term DNA damage and supra-additive  levels of
toxicity to NAT expressing cells and xenografts may be achieved using
a combination of TPT and [131I]mIBG.  These effects are dependent on
the scheduling of the two agents.
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OESTROGEN MODULATION OF A RADIATION-INDUCED 
BYSTANDER EFFECT IN TARGETED BREAST CELLS
C Shao 1, KD Held 2, M Folkard 1, BD Michael 1, KM Prise 1
1 Gray Cancer Institute, PO Box 100, Mount Vernon Hospital,
Northwood, Middlesex, HA6 2JR, United Kingdom, 2 Dept. Radiation 
Oncology, Cox 301, Massachusettes General Hospital, Harvard 
Medical School, Boston, United States
The observation of radiation-induced  bystander responses where
cells respond to their neighbours being irradiated may indicate an
opportunity to modulate the efﬁ  cacy of radiotherapy. Only limited data
have been published on radiation-induced bystander effect in tumour 
cells and t he mechanisms underpinning t hese responses are poorly
understood. In the present study, we used the Gray Cancer Institute
Charged Particle Microbeam to target precise numbers of helium ions
(3He2+) to a fraction of cells within a population of human breast cancer 
cells of either ER-positive MCF-7 or ER-negative MDA-MB-231. It
was found that when a fraction from 1% to 100% of the cells within the
population was individually targeted, the yields of micronucleus (MN)
of both cell lines were higher than the predicted values assuming no
bystander effect. Treatment with 17β-oestradiol (E2) had no effect on
the response of the MDA-MB-231 cells. However, treatment of MCF-
7 cells with E2 increased both radiosensitivity and the extent of the
radiation-induced bystander response. Both these increased responses
were switched off when tamoxifen was present during the E2 treatment,
and tamoxifen alone had no inﬂ   uence on the radiation response.
Moreover, treatment of MCF-7 cells with L-NAME, a non-selective
NOS inhibitor, decreased the yield of bystander MN, and reduced the
yield of MN in the population where 100% of cells were targeted with
1 particle but not ﬁ  ve particles. This suggests that at low doses the
response to radiation is a combination of direct and bystander pathways.
Unexpectedly, the L-NAME treatment did not signiﬁ  cantly diminish
the E2-enhanced radiosensitivity and bystander response. Our results
indicate that more than one bystander mechanism may be functional
within irradiated MCF-7 tumour cells.
P80
THE INFLUENCE OF THE OESTROUS CYCLE ON THE
RADIATION RESPONSE OF SOLID TUMOURS
PR Swann, DJ Garvey, BA Telfer, IJ Stratford 
University of Manchester, Manchester, United Kingdom
Oestrogen  increases the transcription of n itric oxide synthase, thus
increasing nitric oxide production, which can result in vasodilation.
Fluctuating levels of oestrogen throughout the menstrual cycle has the
potential to affect tumour blood ﬂ  ow. Variations of blood supply to a
solid tumour can inﬂ  uence the percentage of hypoxic cells and therefore
the radiation response of the tumour. The current study has evaluated the
impact of the oestrous stage on the radiation response of KHT tumours
in syngeneic C3H mice. The oestrous cycle consists of the stages, pro-
oestrus, oestrus, metoestrus and dioestrus. Oestrogen levels peak in
oestrus and fall in dioestrus. Each stage was determined by the cellular
composition of vaginal smears.
Tumours were locally  irradiated w ith 10 Gy ionising radiation at
different stages of the oestrous cycle. Tumour cell survival was assessed
by clonogenic assay of the excised tumour relative to untreated tumours
excised at the corresponding oestrous stage. Untreated KHT tumours
excised in oestrus consistently showed an increased colony forming
efﬁ  ciency compared to those excised at other stages of t he cycle.
Tumours excised immediately after irradiation in metoestrus, showed
a ﬁ  ve-fold increase in surviving fraction compared to those irradiated
in oestrus.
The oestrous stage dependent effect on potentially lethal damage repair
(PLDR) in KHT tumours was evaluated. The overall surviving fraction
of tumours excised either immediately or 24 hours after irradiation was
similar. However, the KHT tumour indicated a difference in PLDR
corresponding with oestrous stage. Tumours irradiated in pro-oestrus,
oestrus and dioestrus showed an increase in surviving fraction when
excised 24 hours post irradiation, whereas tumours irradiated in
metoestrus showed a reduction in the surviving fraction. The results
presented here suggest that there are oestrous stage dependent effects
that could alter the radiation response of tumours.
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RADIOPROTECTIVE GENE THERAPY FOR THE
HAEMOPOETIC COMPARTMENT
T Southgate 1, V Sheard 1, MD Milsom 1, RJ Mairs 2, M Boyd 2,
LJ Fairbairn 1
1 United Kingdom, Paterson Institute for Cancer Research, Manchester,
2 United Kingdom, Dept of Radiation Oncology, Cancer Research UK 
Beatson Laboratories, Glasgow
Overexpression of manganese superoxide dismutase (MnSOD) has
been hypothesized to provide haemopoietic cells with radioprotection
through t he scavenging of oxygen radicals  induced  by  ionizing
radiation. For this study the human MnSOD cDNA was cloned within a
retroviral construct (SFβ91) with eGFP as a marker. Retroviral producer 
lines were established and used to infect the human erythroleukaemic
cell line, K562, and murine bone marrow.   
Western blot analysis was used to conﬁ  rm expression of MnSOD in
target cells. Whereas control, GFP-only cells exhibited undetectable
levels of MnSOD, those transduced with the SFβ91-SOD2-EGFP
vector showed high levels of protein. Moreover, cells transduced with
the SFβ91-SOD2-EGFP vector show MnSOD activity, whilst control
cells have no detectable activity.
In transduced K562 cells,  an approximately 2-fold survival advantage
is sen for MnSOD-expressing cells over controls when exposed to
varying doses of ionising radiation. Our ﬁ  ndings are encouraging for 
the development of MnSOD gene transfer for the protection against
myelotoxic side effects of radiation.
P80:2
H2AX NUCLEAR FOCI ARE INDUCED IN HUMAN
CELLS AFTER TREATMENT WITH DNA INTERSTRAND
CROSSLINKING CHEMOTHERAPEUTICS
PH Clingen, J Wu, KM Prise, JA Hartley
1 United States, Cancer Research UK Drug-DNA Interactions Research
Group, Royal Free and University College Medical School, London,
2 United Kingdom, Cell and Molecular Biophysics Group, Cray Cancer 
Institute, London
Histone H2AX is rapidly phosphorylated (γ-H2AX), forming discrete γ-H2AX),  forming  discrete  γ
nuclear foci after exposure to ionising radiation. Using antibodies against
γ-H2AX the number of nuclear foci is directly related to the number of γ-H2AX the number of nuclear foci is directly related to the number of  γ
DNA double strand breaks (dsbs). γ-H2AX has been strictly associated γ-H2AX has been strictly associated  γ
with this type of DNA damage and plays a critical role in the recruitment
of DNA repair factors to these nuclear foci.  The aim of this study was to
determine if γ-H2AX foci are induced in human cells following exposure γ-H2AX foci are induced in human cells following exposure  γ
to DNA interstrand crosslinking chemotherapeutics.
Primary  human  ﬁ  broblasts  (AGO1522B) were treated w ith  ionising
radiation (1 gray), cis-platin (5-100 µM) or nitrogen mustard (5-20 µM,
1 hour incubation at 37 oC).  Cells were ﬁ  xed immediately, 4, 8, 24 or
48 hours after ionising radiation or drug treatment and stained with
anti phospho-H2AX and alexa ﬂ  uor 488.  γ-H2AX foci were detected γ-H2AX foci were detected  γ
by immunoﬂ  uorescence microscopy after treatment with cis-platin and
nitrogen mustard.  With ionising radiation foci were evident immediately
after irradiation.  After 8 hours no foci were detected indicating that all
the double strand breaks had been repaired. Pulse ﬁ  eld gel electrophoresis
(PFGE) and t he modiﬁ  ed comet assay were performed to follow the
induction and repair of dsbs and ICLs respectively.  We have previously
shown that dsbs are induced in cells following nitrogen mustard but not
cis-platin treatment.  With both agents γ-H2AX foci formation closely γ-H2AX foci formation closely  γ
follows the formation of DNA ICLs. 
In conclusion, γ-H2AX foci can be observed in the absence of DNA dsbs. γ-H2AX foci can be observed in the absence of DNA dsbs.    γ
This approach could lead to a rapid and sensitive method to detect ICLs
in clinical samples.  Conventional approaches for measuring DNA ICLs,
although quantitative, lack the necessary sensitivity and resolution to
follow DNA damage and repair at the molecular level.
P80:3
H2AX PHOSPHORYLATION AS A MARKER OF DNA DAMAGE
FOLLOWING DIAGNOSTIC AND THERAPEUTIC IRRADIATION
IN VIVO
KM Rothkamm, S Balroop, F Daley
United Kingdom, Gray Cancer Institute, Northwood
Ionising radiation induces a broad spectrum of damages in our genes,
of which DNA double-strand breaks (DSBs) are considered to be the
most relevant lesion for cell killing, chromosome aberration formation
and cancer induction. One of the earliest steps in the cellular response
to DSBs is the phosphorylation of H2AX, a subclass of histone proteins
that are part of the DNA-protein complex called chromatin. Using a
ﬂ  uorescent  antibody speciﬁ   c for the phosphorylated form gamma-
H2AX and immunoﬂ  uorescence  microscopy, discrete nuclear foci
can be visualized at sites of DSBs. Recent cell culture studies have
demonstrated that gamma-H2AX expression not only monitors the
formation of DSBs but can also be exploited as a measure for the repair 
of radiation-induced DSBs at physiologically relevant doses. The aim
of this study was to determine the usefulness of gamma-H2AX analysis
for visualising DSBs after in vivo exposure to low or moderate doses
of ionising radiation. To this end, immunoﬂ  uorescence  microscopy
for gamma-H2AX was performed in leukocytes from blood samples
of patients receiving routine CT scans to assess the DNA damage that
is produced in the patient’s body during these treatments. To study
gamma-H2AX expression in different tissues, tissue arrays prepared 
from different organs of irradiated mice were immunohistochemically
stained to visualise gamma-H2AX foci in situ. The results demonstrate
that  gamma-H2AX analysis enables studies of DNA damage and 
repair to be performed following in vivo exposure to diagnostic and 
therapeutic radiation doses.
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THE ROLE OF MYCN AMPLIFICATION AND HYPOXIA IN THE
EXPRESSION OF FACILITATIVE GLUCOSE TRANSPORTERS 
IN NEUROBLASTOMA CELL LINES LILILINESROBLASTOMA 
CELL LINES
A Lunt 1, A Evans 1, P Houghton 2, I Stratford 3, E Estlin 4, R Airley 1
1 Liverpool John Moores University, Liverpool, United Kingdom, 
2 St Judes Childrens Research Hospital, Memphis, United States, 
3 University of Manchester, Manchester, United Kingdom, 4 Royal
Manchester Childrens Hospital, Manchester, United Kingdom
Tumour hypoxia upregulates genes such as the facilitative glucose transporters
Glut-1 and Glut-3, both these genes predicting poor prognosis and increased
likelihood of metastasis in a range of solid tumours.  Oncogenes that code for
transcription factors such as cMyc show  homology with hypoxia-inducible
factor HIF-1α, and therefore may cause constitutive expression of hypoxia-
inducible genes. In neuroblastoma, the MYCN oncogene is associated with
poor prognosis.  Previously, we have shown Glut-1 to be present in a proportion
of clinical samples of cases of neuroblastoma, and that this may correlate with
the MYCN ampliﬁ  cation.  To investigate the inﬂ  uence of MYCN ampliﬁ  cation
on hypoxia-regulated genes, a study was carried out using MYCN ampliﬁ  ed
(NB-SD, NB-1691) and the single copy MYCN expressing (NB-EB)
neuroblastoma cell lines. Immunohistochemistry of formalin-ﬁ  xed, parafﬁ  n-
embedded pellets of cells exposed to 18 hours normoxia or 0% O2was used
to evaluate the presence of Glut-1, Glut-3, and Glut-4. In MYCN ampliﬁ  ed
cells, there was a low  level o f constitutive Glut-1 expression, which was
up-regulated to moderate levels in anoxia. However, the single copy MYCN
cell line (NB-EB) only expressed Glut-1 after exposure to anoxia.  Glut-3
expression was only found at low levels in the NB-EB cell line, the levels
being increased to moderate levels after exposure to anoxia. There was no
detectable Glut-3 in the MYCN ampliﬁ  ed cell lines. Glut-4, which is not HIF-
1 regulated but is able to translocate from intracellular vesicles to the plasma
membrane in hypoxic conditions, was not detectable in these cell lines.  This
study provides preliminary evidence that MYCN ampliﬁ  cation and hypoxia
may work together to control t he expression of  hypoxia-regulated genes
in neuroblastoma.  Further investigations will aim to clarify how MYCN
ampliﬁ  cation with or without tumour hypoxia may control the behaviour of
neuroblastoma and inﬂ  uence treatment response and prognosis
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IS HYPOXIA A THERAPEUTIC TARGET IN HAEMATOLOGICAL
MALIGNANCIES? GLUT-1 AND LDH EXPRESSION IN ACUTE
LYMPHOBLASTIC LEUKAEMIA
K Santos 1, A Evans 1, A Kelsey 2, R Wynn 2, E Estlin 2, R Airley 1
1 Liverpool John Moores University, Liverpool, United Kingdom,
2 Royal Manchester Childrens Hospital, Manchester, United Kingdom
Hypoxia traditionally occurs within solid tumours due to the high rate of 
cell proliferation and poor blood supply. It is associated with radio and 
chemoresistance, poor prognosis and metastasis. Hypoxia is not associated 
with leukaemia since it does not form solid tumours; however, these cells
originate from within the bone marrow, in which a low oxygen tension is
possible due to the high proliferation of these lymphoid cells. Therefore,
hypoxia in the bone marrow may inﬂ  uence the downstream behaviour of 
leukaemic cells. We are therefore carrying out studies to investigate the
expression of the hypoxia-regulated genes Glut-1 and lactate dehydrogenase
(LDH) in acute lymphoblastic leukaemia (ALL). We have previously
validated Glut-1 as a marker of hypoxia and a marker of prognosis in
advanced carcinoma of the cervix, oral squaemous carcinoma and colorectal
tumours. Raised serum LDH is a poor prognostic indicator in ALL. Further,
tissue LDH-5 predicts poor prognosis in non-small cell lung cancer. LDH-
1 is found in all cells, malignant and normal, and due to its low catalytic
activity promotes the insertion of pyruvate into the Kreb’s Cycle to facilitate
aerobic oxidative phosphorylation. LDH-5, however,  has  high catalytic
activity. Therefore, where oxygen is lacking, anaerobic glycolysis may be
accompanied by an increased rate of conversion of pyruvate to lactate by
LDH-5. So far, the pattern of expression of Glut-1 and LDH isoforms in
haematological malignancies is poorly understood. To address this, Glut-1,
LDH-1 and LDH-5 expression is currently being investigated in clinical
samples and formalin-ﬁ  xed, parafﬁ  n-embedded cell pellets of MOLT-4 (T-
cell) and NALM-6 (B-cell) ALL cell lines that have been exposed to anoxia.
In a series of trephine biopsies taken from children with ALL, Glut-1 protein
was detected in lymphoblasts of 3/10 cases. By characterising the pattern of 
expression of these hypoxia-dependent genes we may be able to predict the
inﬂ  uence of hypoxia in haematological malignancies, as well as the relative
levels of acute and chronic hypoxia existing in clinical samples.
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HYPOXIA-REGULATED PROTEINS (HRPS) AND MATRIX 
METALLOPROTEINASES (MMPS) IN  GASTRIC CANCER: 
IMPACT  ON  MALIGNANT  PROGRESSION
S.P. Osinsky, L.N. Bubnovskaya, I.I. Ganusevich, A.V . Kovelskaya,
O.V . Yurchenko, N.V . Valkovskaya, D.S. Osinsky, L.D. Gumenyuk, 
V .A. Chorny 
Inst. exp. Pathol. Oncol. Radiobiol., Natl Acad, Sci. of Ukraine,
Kiev, Ukraine
Aim: to evaluate the interrelationship between hypoxia level, expression of
HRPs and activity of  MMPs in tumor tissue and assess the impact of these
parameters on  malignant progression. 
Patients&Methods:  43 gastric cancer patients who underwent primary
surgery were included in the study. All patients gave written consent before
samples were obtained. Activity of MMPs (MMP-2 and -9) in tumor was
determined with biochemical methods; hypoxia within tissue was evaluated
using 31P NMR spectroscopy, expressions of hypoxia-inducible factor-
1alpha (HIF-1alpha) and CD34 (microvessel density) in tissue were assessed
using immunohistochemistry. All human tumor indices were measured
immediately after surgery. Lewis lung carcinoma (3LL) was  investigated in
model experiments too.
Results: The positive correlation between hypoxia level and MMPs activity
in primary tumor of 3LL tumor-bearing mice was observed. Both indices
had positively impact on lung metastases. The hypoxia level assessed with
31P NMR  correlated with HIF-1alpha expression in human gastric cancer
(HGC). The direct correlation between hypoxia level, tumor stage and CD34
expression was determined in HGC. Tumor MMPs activity was signiﬁ  cantly
higher than that in the surrounding normal mucosa. It was not observed the
correlation  between MMPs activity and CD34 expression  in tumor. The
signiﬁ  cant correlation between tumor hypoxia and MMPs activity was not
determined. It may be suggested that MMPs activity is not directly affected
by hypoxia in HGC. It was not observed the correlation between  MMPs
activity and  tumor stage. Hypoxia  level and MMPs activity positively
correlated with disease-free termin and metastases. 
Conclusion: Hypoxia positively impacts on malignant progression. HIF-
1alpha and CD34 expressions and MMPs activity in tumor tissue may be
exploited as an prognostic markers for clinical outcome.
Acknowledgement: the study was supported by  SNFS  (SCOPES).
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INVESTIGATION OF THE ROLE OF GLUCOSE
TRANSPORTER-1, AS A MARKER FOR TUMOUR HYPOXIA,
IN NEO-ADJUVANT RADIOTHERAPY OF RECTAL CANCER
NP Yeomans, MC Bibby, RM Phillips, JP Grifﬁ  th, JB Davies
United Kingdom, The University of Bradford, Bradford
Neo-adjuvant short course, high dose radiotherapy is advocated for local
control, reduced recurrence and improving survival in certain rectal
adenocarcinomas, when compared to surgery alone.  The representative
volume of hypoxic cells in colorectal cancers is reported to vary from as
little as 1% to over 80% which leads to an adaptation towards anaerobic
metabolism, via glycolysis, and tumour radio-resistance.  Glucose
transporter-1 (Glut-1) is the main transmembrane glucose transporter 
up-regulated in many human cancers and is one of many transcription
factors of hypoxia inducible factor-1 (HIF-1).
In this preliminary series of 20 patients receiving neo-adjuvant
radiotherapy for rectal cancer there was no signiﬁ  cant difference in
the tumour hypoxic fraction before and after radiotherapy but with
a broad range of 0.5% to 28% (mean 6%) as indicated by Glut-1
immunohistochemical tissue section staining.  
There was no signiﬁ  cant difference in hypoxic fraction when compared 
to Dukes’ or T stage but those deemed to have a good response to
radiotherapy did have a lower hypoxic fraction when compared to the
other rectal tumours.
P85
HYPOXIA DRIVEN TNF-α  GENE THERAPY 
EJ Garside, R Cowen, K Williams, N Chadderton, IJ Stratford 
Experimental Oncology, Department of Pharmacy and Pharmaceutical
Sciences, University of Manchester, Manchester, United Kingdom
TNFα has strong anticancer activity but systemic toxicity limits its clinical
use. Hypoxia responsive elements (HREs) can be used to drive gene
expression in hypoxia. Salloum et al (2003) used the erythropoietin HRE
(Epo) with Egr1 to drive TNFα. In our experience this promoter gives high
aerobic expression that prevents its systemic use. Here we present a hypoxia
responsive adenovector Ad LDH TNF that carries a synthetic HRE promoter
derived from lactate dehydrogenase (LDH). We have previously demonstrated
the utility of this promoter in a hypoxia driven GDEPT strategy (Cowen et al
2004, Cancer Res.). In transient plasmid transfection experiments we have
compared the LDH and Epo-Egr1 promoters driving expression of luciferase
in aerobic and hypoxic tumour cells in vitro. The LDH promoter silences
reporter gene expression  in aerobic tumour cells compared to EpoEgr1
[HCT116 (colon carcinoma) 6 fold ↓ and HT1080 (ﬁ  brosarcoma) 3 fold ↓
]. Unlike other tumour speciﬁ  c promoters absolute levels of expression are
not compromised once the LDH promoter is stimulated by O2 tensions at
or below 1% O2. In comparison to the Epo-Egr1 promoter the strength of
expression is equivalent in the HT1080 cells and 50% higher in the HCT116
cells. When we replace the luciferase gene with the cDNA for human TNFα
we are able to confer tight hypoxic control. In supernatants taken from
aerobic HCT116 and HT1080 cells transfected with pLDH TNFα we are
unable to detect TNFα. However, cells stimulated by hypoxia (0.001% O2) or
1% O2 secrete high levels of the cytokine (HT1080 ~ 3618 and 3215 pg/ml;
HCT116 ~ 5395 and 6170 pg/ml) In contrast TNFα secretion from Epo-Egr1
was independent of O2 concentration (HT1080 ~ 1306, 6439, 4794 pg/ml
and HCT116 ~ 5498, 7712, 8362 pg/ml in air, hypoxia and 1% O2). We are
now generating adenovectors to deliver luciferase or TNFα with expression
driven by LDH or Epo-Egr-1. Using these viral vectors we will undertake in
vivo studies and envisage that aerobic silencing will translate into tumour
speciﬁ  c expression when delivered with minimal unwanted expression in
normal tissues.
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SCREENING OF POTENTIAL HIF-1 MODULATOR DRUGS
IN HCT116 CELL LINE : MORE TOXICITY THAN SPECIFIC
INHIBITION OF HIF-1
C Debray, KJ Williams, R Cowen, IJ Stratford 
Experimental Oncology, School of Pharmacy and Pharmaceutical 
Sciences, University of Manchester, Manchester, United Kingdom
Hypoxia-inducible factor 1 (HIF-1) is a key transcription factor in the
regulation of the response to hypoxia. Its upregulation in many solid 
tumours and its involvement in tumour progression make it a potential
target  for anticancer therapy. It binds to hypoxia response elements
(HRE) present in the promoters of genes controlling angiogenesis,
cell proliferation and cell survival. Recent works suggest that HIF-
1 can be regulated by the PI3K/Akt and the MAPK pathways and 
by the association with the molecular chaperone heat shock protein
90 (Hsp90). We tested a range of drugs that have been proposed to
modulate HIF-1 driven gene expression. These include drugs targeting
the PI3K pathway (LY294002, Wortmannin, Rapamycin), the MAPK 
pathway  (PD98059), the Hsp90-speciﬁ  c inhibitor geldanamycin and 
YC-1. We have  developed a human colon adenocarcinoma HCT116
stable cell line engineered to encode for an HRE driven ﬁ  reﬂ  y
luciferase gene and importantly a constitutive promoter driven renilla
luciferase cassette as an internal control. We quantiﬁ  ed  ﬁ  reﬂ  y  and 
renilla luciferase in the presence of each drug with and without the
hypoxia mimetic CoCl2. The toxicity of these molecules was evaluated 
by MTT survival assays. At drug concentrations shown to modulate
HIF-1 in the literature in our screen most of the drugs had only a toxic
effect and no speciﬁ  c inhibition of HIF-1 activity. Geldanamycin was
toxic at 5-10 nM and did not inhibit HIF-1 at non toxic concentrations.
LY294002 and Rapamycin showed neither toxicity nor inhibitory
effect and Wortmannin and YC-1 modestly decreased HIF-1 activity in
CoCl2 conditions. However, PD98059 showed a speciﬁ  c inhibition of 
HIF-1 activated ﬁ  reﬂ  y luciferase expression that was greater in CoCl2
condition. The exact mechanisms of this inhibition are currently under 
investigation.
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THE ROLE OF HYPOXIA AND  THE TRANSCRIPTION FACTOR 
HIF- 1 IN THE DEVELOPMENT OF METASTASIS
LK Whitney, KJ Williams, IJ Stratford, SJ Lunt, L Brown
Experimental Oncology, Department of Pharmacy and Pharmaceutical
Sciences, University of Manchester, Manchester, United Kingdom
Tumour hypoxia and the hypoxic/HIF-1 signalling pathway have been
linked to an increased incidence of metastases. To investigate the role
of HIF-1 in metastatic potential we are utilising the syngeneic murine
melanoma B16 F1/C57BL6 metastatic model that reproducibly forms
metastases at various sites  following  irradiation of subcutaneous
primary tumours. We have transiently transfected B16 F1 cells in vitro
with a hypoxia responsive luciferase reporter plasmid to conﬁ  rm that
the cell line has an intact hypoxic response and witnessed up to a 500-
fold induction in luciferase following a hypoxic (0.001% O2) stimulus.
This paved the way for the generation of a HIF-1 responsive metastatic
reporter cell line. The cell line was generated by stable integration of
a lacZ expression cassette whose promoter contains synthetic hypoxia
responsive enhancer elements  from murine phosphoglycerate  kinase
(PGK HRE). The process of clonal selection had not diminished the
metastatic potential, and both Z16 primary and metastatic tumours
stain positive for beta galactosidase expression that co-localises with
the hypoxic marker pimonidazole. We are currently generating a stable
cell line that constitutively expresses beta galactosidase by inserting
the lacZ cDNA into pEF IRES puro an optimised vector for stable cell
line generation. Having established the model to investigate the HIF-
1  dependency of metastases formation we have created a dominant
negative form of HIF-1 alpha that is constitutively expressed and
lacks the oxygen degradation and transactivation domains. Transient
co-transfections in B16 F1 cells with the dominant negative and a
PGK HRE luciferase reporter plasmid demonstrates functionality of
the dominant negative inhibiting luciferase expression in hypoxic cells
down to basal aerobic levels. Stable cell lines are now being generated
by integration of the dominant negative cassette into the Z16 cells.
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MANIPULATION OF TUMOUR HYPOXIA USING TNF ALPHA 
GENE THERAPY TO POTENTIATE BIOREDUCTIVE DRUGS
AND/OR HYPOXIA DRIVEN GENE THERAPY 
RL Cowen, E Garside, KJ Williams, FC Sheppard, BA Telfer,
M Jaffar, IJ Stratford 
United Kingdom, University of Manchester, Manchester
The refractive nature of hypoxic tumour cells to current anti-cancer 
treatments makes them an attractive target for novel gene therapies.
Our group’s approach  has  been to hijack t he  hypoxic/HIF pathway
by using it as a trigger for tumour selective gene therapy. HIF initiates
transcription via  hypoxia responsive enhancer elements  (HREs)
therefore by engineering synthetic HREs into therapeutic cassettes we
have been able to confer hypoxic tumour speciﬁ  city to both adenoviral
delivered enzyme/prodrug (P450 reductase/Tirapazamine) and suicide
(TNF alpha) gene therapy approaches. 
The tumour vascular system is responsible for the oxygenation of cells
therefore  by targeting endothelial cells we can manipulate tumour 
hypoxia. Interestingly, the tumour endothelium is the proposed target
for TNF alpha. Work  by Edwards et al.,  (1991)  demonstrated t hat
recombinant TNF alpha could induce rapid haemorrhagic necrosis in
murine KHT tumours resulting in tumour hypoxia equivalent to 100%
radiobiological hypoxia. This effect was transient occurring within 1h
of administration and lasting for 16h. Therefore we hypothesise that by
using TNF alpha gene therapy we can potentially increase the efﬁ  cacy
of our hypoxia driven gene therapy approaches.
We are currently determining the inﬂ  uence of the TNF alpha expressing
adenovectors upon endothelial cells and tumour hypoxia in vivo. We
are also  investigating their ability to potentiate  bioreductive  drugs
such as TPZ. Further we envisage a greater than additive effect from
combining our P450 reductase/Tirapazamine and TNF alpha gene
therapy approaches.
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TARGETING HIF-1 TO REVERSE TUMOUR
CHEMO-RESISTANCE
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Hypoxic tumour cells are resistant to many forms of chemotherapy
agents. We are investigating the mechanisms  involved and w hether
targeting HIF-1 using gene therapy will reverse this resistance. We have
determined by MTT assay that hypoxic human HT1080 (ﬁ  brosarcoma)
and HCT116 (colon carcinoma) tumour cells are more resistant to
etoposide than aerobic tumour cells (2-4 fold). This hypoxic resistance
was also observed  in wild-type Hepa-1 (murine  hepatoma) cells.
However, it was not seen in Hepa-1 HIF-1 beta deﬁ  cient cells suggesting
a HIF-1 dependency for resistance. To target HIF-1 we have created a
dominant negative form of HIF-1 alpha (HIF-1 alpha no TAD) that is
constitutively expressed and lacks the transactivation domains. Transient
co-transfection experiments  in HT1080 and HCT116 cells with t he
HIF-1 alpha no TAD and the hypoxia responsive (PGK HRE) luciferase
reporter expression plasmids demonstrate functionality of the dominant
negative.  We have also created a HIF-1 alpha no TAD/GFP fusion and
have  demonstrated t hat GFP ﬂ  uorescence and  inhibition of  hypoxia
driven luciferase expression is not compromised.  GFP tagging has also
conﬁ  rmed that the dominant negative is nuclear localised in aerobic and
hypoxic cells. We have inserted this fused cDNA into pEF IRES puro an
optimised vector for stable cell line generation. We have also engineered
a replication defective adenovector Ad HIF-1 alpha no TAD. Using the
virus we can re-capitulate the plasmid experiments inhibiting hypoxia
driven luciferase expression in a viral dose dependent manner. Further,
we show that we can reverse hypoxia mediated etoposide resistance in
HT1080 and HCT116 by infection with Ad HIF-1 alpha no TAD two
days prior to drug exposure. We aim to extend these observations to
other agents and  investigate whether targeting HIF-1 transactivation
using Ad HIF-1 alpha gene therapy can modify drug response in vivo.
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P43/EMAP-II EXPRESSION IN COLORECTAL CANCER IS
ASSOCIATED WITH HYPOXIA AND ENHANCED LYMPHOCYTE
INFILTRATION
M Saber, P Symonds, JC Murray
Wolfson Digestive Diseases Centre, Queen’s Medical Centre,
Nottingham University, Nottingham, United Kingdom
AIMS: P43/Endothelial monocyte–activating polypeptide-II  (p43/EMAP-
II) is a proinﬂ  ammatory cytokine and a chemoattractant for mononuclear 
phagocytes and polymorphonuclear leucocytes, found in culture supernatants
of many tumour cell lines. We recently demonstrated that p43/EMAP-II
induces apoptosis in mitogen-stimulated lymphocytes, and suggested that
it may be a constituent of a novel immune evasion mechanism employed 
by tumour cells (1). Furthermore p43/EMAP-II release is enhanced by
hypoxia (2).  Our study has examined the association between p43/EMAP-II
expression and hypoxia in colorectal cancer (CRC), and also the association
between p43/EMAP-II and tumour cell apoptosis.
METHODS: Formalin-ﬁ  xed, parafﬁ  n-embedded archival t issue samples
from 72 patients diagnosed with colorectal tumours was used in immuno-
histochemical studies.  Antibodies against p43/EMAP-II, carbonic anhydrase
(CA IX) as a surrogate marker of hypoxia, and CD3 to identify lymphocytes,
were used.  Areas of p43/EMAP-II and CA IX staining were quantiﬁ  ed using
computer-aided image analysis.
RESULTS: P43/EMAP-II expression was correlated with CA IX expression
in CRC (p (p ( =0.03).  Patients with high p43/EMAP-II expression seemed to
do better than those with low, and the reverse was true for CA IX.  There
was also a positive correlation between p43/EMAP-II and the lymphocyte
counts in CRC (p (p ( =0.02), as well as between CA IX and lymphocyte counts.
The presence of CD3+ve cells was a good prognostic indicator in terms of 
overall survival. 
CONCLUSIONS: P43/EMAP-II expression is associated with hypoxia
in colorectal cancer, and with high lymphocyte counts.  We are currently
determining the relationship between p43/EMAP-II expression and the
functional state of the lymphocyte population.
(1) Murray et al. (2004). J Immunol 172: 274.
(2) Barnett et al. (2000). Cancer Research 60: 2850.
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